NCT03728881View on ClinicalTrials.gov

Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

1,240

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

September 30, 2022

Study Completion Date

April 23, 2024

Conditions
Human Papillomavirus-Related Cervical Carcinoma
Interventions
BIOLOGICAL

Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine

Given IM

BIOLOGICAL

Recombinant Human Papillomavirus Bivalent Vaccine

Given IM

Trial Locations (1)

50101

Agencia Costarricense de Investigaciones Biomédicas (ACIB), Liberia

Sponsors

Collaborators (1)

Cancer Research UK
All Listed Sponsors
collaborator

Cancer Research UK

OTHER

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

National Cancer Institute (NCI)

NIH

NCT03728881 - Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial | Biotech Hunter | Biotech Hunter